Non-Cochrane · intervention · PM42330716
The Efficacy of Mesenchymal Stem Cell-Based Therapy for Sjögren's Syndrome: A Systematic Review and Meta-Analysis of Preclinical Studies.
Yang Xinyue, Shi Cheng, Wu Zhuoyang, et al. · International dental journal · 2026 · PubMed · doi:10.1016/j.identj.2026.109688
Findings
50 findings
| Population | ||||
|---|---|---|---|---|
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | IFN-γ level in serum Preclinical, in vivo (mouse) · Measurement site | SMD -0.97 [-1.66, -0.27] GRADE not reported 3 studies · 38 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | IL-6 level in salivary gland tissue Preclinical, in vivo (mouse) · Measurement site | SMD -3.10 [-5.35, -0.85] GRADE not reported 3 studies · 44 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · All interventions combined | SMD 3.19 [2.50, 3.88] GRADE not reported 16 studies · 374 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, percentage of total area Preclinical, in vivo (mouse) · Assessment unit | SMD -1.94 [-2.96, -0.92] GRADE not reported 7 studies · 170 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | IL-10 level measured by ELISA Preclinical, in vivo (mouse) · Measurement site | SMD 4.15 [-1.26, 9.56] GRADE not reported 2 studies · 24 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Interleukin-10 (IL-10) level Preclinical, in vivo (mouse) · Serum, salivary gland and ELISA datasets combined | SMD 2.44 [0.90, 3.98] GRADE not reported 7 studies · 158 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, percentage of total area, Aluri 2017 excluded Preclinical, in vivo (mouse) · Intervention type analysis, MSCs and exosomes combined | SMD -2.10 [-3.41, -0.80] GRADE not reported 6 studies · 130 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | IL-6 level in serum Preclinical, in vivo (mouse) · Measurement site | SMD -1.92 [-3.18, -0.65] GRADE not reported 8 studies · 94 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, number of lymphocytic foci Preclinical, in vivo (mouse) · Assessment unit | SMD -5.62 [-10.75, -0.48] GRADE not reported 5 studies · 68 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Interferon-gamma (IFN-γ) level Preclinical, in vivo (mouse) · Serum and salivary gland combined | SMD -2.20 [-3.51, -0.89] GRADE not reported 4 studies · 74 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, focus score Preclinical, in vivo (mouse) · Assessment unit | SMD -2.02 [-2.66, -1.39] GRADE not reported 8 studies · 76 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | IFN-γ level in salivary gland tissue Preclinical, in vivo (mouse) · Measurement site | SMD -4.11 [-6.14, -2.08] GRADE not reported 3 studies · 36 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | IL-10 level in salivary gland tissue Preclinical, in vivo (mouse) · Measurement site | SMD 0.13 [-2.80, 3.06] GRADE not reported 3 studies · 44 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, area ratio of lymphocyte infiltration Preclinical, in vivo (mouse) · Assessment unit | SMD -3.77 [-5.27, -2.27] GRADE not reported 6 studies · 42 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, histological score Preclinical, in vivo (mouse) · Assessment unit | SMD -0.81 [-1.64, 0.01] GRADE not reported 3 studies · 36 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Interleukin-6 (IL-6) level Preclinical, in vivo (mouse) · Serum and salivary gland combined | SMD -2.25 [-3.29, -1.22] GRADE not reported 7 studies · 138 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | IL-10 level in serum Preclinical, in vivo (mouse) · Measurement site | SMD 3.37 [1.20, 5.55] GRADE not reported 6 studies · 90 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Any MSC-based therapy (MSCs, MSC-derived exosomes, or MSC-conditioned medium) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration Preclinical, in vivo (mouse) · All histological measures combined | SMD -2.04 [-2.66, -1.43] GRADE not reported 18 studies · 392 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Follow-up analysis, both follow-up categories combined | SMD 2.86 [2.02, 3.70] GRADE not reported 17 studies · 228 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Meta-regression moderator: follow-up duration | Meta-regression coefficient 0.54 [-1.64, 2.72] GRADE not reported 13 studies |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | IL-6 level in serum Preclinical, in vivo (mouse) · Intervention type | SMD -1.27 [-2.14, -0.39] GRADE not reported 6 studies · 78 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC dose analysis, all dose categories combined | SMD 3.21 [2.00, 4.43] GRADE not reported 13 studies · 156 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Meta-regression moderator: MSC type | Meta-regression coefficient 2.13 [0.49, 3.76] GRADE not reported 13 studies |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, percentage of total area Preclinical, in vivo (mouse) · Intervention type, Aluri 2017 excluded | SMD -3.02 [-3.76, -2.27] GRADE not reported 4 studies · 70 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Follow-up 12 weeks or longer · Preclinical, in vivo (mouse) · Follow-up duration | SMD 2.41 [1.32, 3.49] GRADE not reported 5 studies · 90 participants |
| NOD mouse models of Sjögren's syndrome | Mesenchymal stem cells (cell therapy) | Control (no MSC-based treatment) | Stimulated salivary flow rate (SFR; standardized to uL/10 min) Laboratory animal studies (NOD mice) | SMD 2.85 [2.04, 3.67] GRADE not reported 19 studies · 244 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC source analysis, BM-MSC, LG-MSC and UC-MSC datasets combined | SMD 2.51 [1.76, 3.26] GRADE not reported 15 studies · 198 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Follow-up under 12 weeks · Preclinical, in vivo (mouse) · Follow-up duration | SMD 3.31 [2.03, 4.58] GRADE not reported 12 studies · 138 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | IL-10 level in serum Preclinical, in vivo (mouse) · MSC dose analysis, all dose categories combined | SMD 3.02 [1.24, 4.80] GRADE not reported 5 studies · 80 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Mesenchymal stem cells (whole cells) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Meta-regression moderator: MSC dose | Meta-regression coefficient -4.31 [-7.10, -1.53] GRADE not reported 13 studies |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSC-derived exosomes | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Exosome source analysis, DPSC and LG-MSC exosome datasets combined | SMD 5.59 [1.82, 9.35] GRADE not reported 5 studies · 50 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSC-derived exosomes | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Follow-up under 12 weeks · Preclinical, in vivo (mouse) · Follow-up duration | SMD 4.57 [0.92, 8.23] GRADE not reported 4 studies |
| NOD mouse models of Sjögren's syndrome | MSC-derived exosomes | Control (no MSC-based treatment) | Stimulated salivary flow rate (SFR; standardized to uL/10 min) Laboratory animal studies (NOD mice) | SMD 4.22 [2.18, 6.26] GRADE not reported 7 studies · 82 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSC-derived exosomes | Control (non-MSC-treated NOD mice) | Salivary gland inflammatory infiltration, percentage of total area Preclinical, in vivo (mouse) · Intervention type, Aluri 2017 excluded | SMD -0.29 [-0.81, 0.23] GRADE not reported 2 studies · 60 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSC-derived exosomes | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Follow-up 12 weeks or longer · Preclinical, in vivo (mouse) · Follow-up duration | SMD 4.66 [0.44, 8.88] GRADE not reported 3 studies |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSC-derived exosomes | Control (non-MSC-treated NOD mice) | IL-6 level in serum Preclinical, in vivo (mouse) · Intervention type | SMD -10.02 [-15.08, -4.96] GRADE not reported 2 studies · 16 participants |
| NOD mouse models of Sjögren's syndrome | MSC-conditioned medium | Control (no MSC-based treatment) | Stimulated salivary flow rate (SFR; standardized to uL/10 min) Laboratory animal studies (NOD mice) | SMD 3.68 [2.14, 5.22] GRADE not reported 4 studies · 48 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Bone marrow-derived MSCs (BM-MSC) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC source | SMD 2.50 [1.56, 3.44] GRADE not reported 8 studies · 102 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Labial gland-derived MSCs (LG-MSC) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC source | SMD 4.78 [0.12, 9.43] GRADE not reported 2 studies · 16 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Umbilical cord-derived MSCs (UC-MSC) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC source | SMD 2.27 [0.93, 3.60] GRADE not reported 5 studies · 80 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Dental pulp stem cell-derived exosomes (DPSC-Exos) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Exosome source | SMD 4.40 [-2.79, 11.58] GRADE not reported 2 studies · 24 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Labial gland MSC-derived exosomes (LG-MSC-Exos) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Exosome source | SMD 6.17 [3.71, 8.63] GRADE not reported 3 studies · 26 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | BM-MSC conditioned medium (BM-MSC-CM) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Conditioned medium source | SMD 2.65 [1.43, 3.88] GRADE not reported 2 studies · 24 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | Dental pulp stem cell conditioned medium (DPSC-CM) | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · Conditioned medium source | SMD 5.29 [3.28, 7.30] GRADE not reported 2 studies · 24 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSCs at dose below 10^6 cells | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC dose | SMD 3.69 [2.41, 4.98] GRADE not reported 7 studies · 76 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSCs at dose of 10^6 cells | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC dose | SMD 1.47 [0.66, 2.27] GRADE not reported 4 studies · 60 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSCs at dose above 10^6 cells | Control (non-MSC-treated NOD mice) | Stimulated salivary flow rate (SFR) Preclinical, in vivo (mouse) · MSC dose | SMD 16.33 [9.66, 23.00] GRADE not reported 2 studies · 20 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSCs at dose above 10^6 cells | Control (non-MSC-treated NOD mice) | IL-10 level in serum Preclinical, in vivo (mouse) · MSC dose | SMD 8.11 [5.17, 11.05] GRADE not reported 2 studies · 24 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSCs at dose above 10^5 and up to 10^6 cells | Control (non-MSC-treated NOD mice) | IL-10 level in serum Preclinical, in vivo (mouse) · MSC dose | SMD 1.97 [1.13, 2.80] GRADE not reported 2 studies · 36 participants |
| Nonobese diabetic (NOD) mouse models of Sjögren's syndrome | MSCs at dose of 10^5 cells or fewer | Control (non-MSC-treated NOD mice) | IL-10 level in serum Preclinical, in vivo (mouse) · MSC dose | SMD 0.70 [-0.21, 1.61] GRADE not reported 1 study · 20 participants |
Included primary studies 25
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Abughanam 2019 Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like… PMID:31557796 | 2019 | this review only | not stated | not extracted yet |
| Aluri 2017 Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Tear Production in a Mouse Model of Sjögren’s Syndrome DOI:10.1155/2017/3134543 | 2017 | this review only | not stated | not extracted yet |
| Chu 2024 <scp>SHED</scp> ‐exos promote saliva secretion by suppressing <scp> <i>p‐</i> ERK1 </scp> /2‐mediated apoptosis in glandular cells DOI:10.1111/odi.14776 | 2023 | this review only | not stated | not extracted yet |
| Cong 2022 Umbilical cord mesenchymal stem cells alleviate Sjögren’s syndrome and related pulmonary inflammation through regulating Vγ4+ IL-17+ T cells DOI:10.21037/atm-22-1855 | 2022 | this review only | not stated | not extracted yet |
| Hai 2018 Inhibitory Effects of iPSC-MSCs and Their Extracellular Vesicles on the Onset of Sialadenitis in a Mouse Model of Sjögren’s Syndrome DOI:10.1155/2018/2092315 | 2018 | this review only | not stated | not extracted yet |
| Hu 2020 Depletion of ID3 enhances mesenchymal stem cells therapy by targeting BMP4 in Sjögren’s syndrome DOI:10.1038/s41419-020-2359-6 | 2020 | this review only | not stated | not extracted yet |
| Hu 2023 Dental pulp stem cell-derived exosomes revitalize salivary gland epithelial cell function in NOD mice via the GPER-mediated cAMP/PKA/CREB… DOI:10.1186/s12967-023-04198-0 | 2023 | this review only | not stated | not extracted yet |
| Huang 2016 DOI:10.3760/cma.j.issn.2095-0160.2016.09.003 | NR | this review only | not stated | not extracted yet |
| Khalili 2010 Bone marrow cells are a source of undifferentiated cells to prevent Sjögren's syndrome and to preserve salivary glands function in the… DOI:10.1016/j.biocel.2010.08.008 | 2010 | this review only | not stated | not extracted yet |
| Khalili 2012 Mesenchymal Stromal Cells Improve Salivary Function and Reduce Lymphocytic Infiltrates in Mice with Sjögren's-Like Disease DOI:10.1371/journal.pone.0038615 | 2012 | this review only | not stated | not extracted yet |
| Kim 2021 Identification of Molecules Responsible for Therapeutic Effects of Extracellular Vesicles Produced from iPSC-Derived MSCs on Sjo¨gren’s… DOI:10.14336/ad.2021.0621 | 2021 | this review only | not stated | not extracted yet |
| Li 2021 Labial gland-derived mesenchymal stem cells and their exosomes ameliorate murine Sjögren's syndrome by modulating the balance of Treg and… DOI:10.1186/s13287-021-02541-0 | 2021 | this review only | not stated | not extracted yet |
| Liu 2021 Human umbilical cord mesenchymal stem cells confer potent immunosuppressive effects in Sjögren’s syndrome by inducing regulatory T cells DOI:10.1080/14397595.2019.1707996 | 2020 | this review only | not stated | not extracted yet |
| Matsumura 2021 Secreted factors from dental pulp stem cells improve Sjögren’s syndrome via regulatory T cell-mediated immunosuppression DOI:10.1186/s13287-021-02236-6 | 2021 | this review only | not stated | not extracted yet |
| Ogata 2021 Dental pulp-derived stem cell-conditioned media attenuates secondary Sjögren's syndrome via suppression of inflammatory cytokines in the… DOI:10.1016/j.reth.2021.01.006 | 2021 | this review only | not stated | not extracted yet |
| Qi 2020 Mesenchymal stem cells inhibited the differentiation of MDSCs via COX2/PGE2 in experimental sialadenitis DOI:10.1186/s13287-020-01837-x | 2020 | this review only | not stated | not extracted yet |
| Ruan 2017 Effect of mesenchymal stem cells on Sjögren-like mice and the microRNA expression profiles of splenic CD4+ T cells. PMID:28587347 | 2017 | this review only | not stated | not extracted yet |
| Shi 2018 Mesenchymal stem cell transplantation ameliorates Sjögren’s syndrome via suppressing IL-12 production by dendritic cells DOI:10.1186/s13287-018-1023-x | 2018 | this review only | not stated | not extracted yet |
| Sun 2022 Mesenchymal stem cell transplantation alleviates Sjögren's syndrome symptoms by modulating Tim-3 expression DOI:10.1016/j.intimp.2022.109152 | 2022 | this review only | not stated | not extracted yet |
| Xie 2025 miRNA let-7f-5p-encapsulated labial gland MSC-derived EVs ameliorate experimental Sjögren’s syndrome by suppressing Th17 cells via… DOI:10.1186/s12951-025-03308-y | 2025 | this review only | not stated | not extracted yet |
| Xing 2022 Labial Gland Mesenchymal Stem Cell Derived Exosomes-Mediated miRNA-125b Attenuates Experimental Sjogren's Syndrome by Targeting PRDM1 and… PMID:35444638 | 2022 | this review only | not stated | not extracted yet |
| Xu 2012 Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome DOI:10.1182/blood-2011-11-391144 | 2012 | this review only | not stated | not extracted yet |
| Yang 2022 Stem cells from exfoliated deciduous teeth transplantation ameliorates Sjögren's syndrome by secreting soluble PD-L1 DOI:10.1002/jlb.6ma0921-752rr | 2021 | this review only | not stated | not extracted yet |
| Yao 2019 Mesenchymal stem cell transplantation alleviates experimental Sjögren's syndrome through IFN-β/IL-27 signaling axis. PMID:31754394 | 2019 | this review only | not stated | not extracted yet |
| Zhao 2023 Inhibitory Effects of Extracellular Vesicles from iPS-Cell-Derived Mesenchymal Stem Cells on the Onset of Sialadenitis in Sjögren's… PMID:36982329 | 2023 | this review only | not stated | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Mouse models of Sjögren's syndrome (animal experiments in mice) | NOD mice (25 studies; 10 to 30 animals per study) |
| Intervention | MSCs, MSC-derived extracellular vesicles (exosomes) or MSC-conditioned medium, given intravenously or intraperitoneally; co-treatment eligible | BM-MSC, UC-MSC, DPSC, SHED, LG-MSC and iPSC-MSC cells (1 x 10^5 to 1 x 10^7 cells), exosomes or conditioned medium (n=25 studies) |
| Comparison | Comparator control group | Non-MSC treated control groups |
| Outcomes | Primary outcome assessing efficacy; SFR, inflammatory infiltration (5 assessment units), IL-6, IL-10, IFN-γ | SFR (n=16 studies); inflammatory infiltration (n=18); IFN-γ (n=4); IL-10 (n=7); IL-6 (n=7) |
| Study designs | Interventional in vivo animal studies published in peer-reviewed journals in English | 25 preclinical animal studies published 2010 to 2025 |
| Timing | Not specified | Follow-up 1 to 52 weeks |
AMSTAR 2 items
Two independent extractors rated each item. Their ratings are shown side by side because they have not been reconciled yet. The overall rating follows Shea et al. 2017: one critical flaw gives Low, more than one gives Critically Low.
| Item | Extractor A | Extractor B | Agree |
|---|---|---|---|
| 1Research question includes PICO components | Yes | Yes | yes |
| 2Protocol established before the reviewcritical | Partial Yes | Yes | no |
| 3Choice of study designs explained | No | No | yes |
| 4Comprehensive literature searchcritical | No | No | yes |
| 5Study selection in duplicate | Yes | Yes | yes |
| 6Data extraction in duplicate | Yes | Yes | yes |
| 7List of excluded studies with reasonscritical | No | No | yes |
| 8Included studies described in detail | Partial Yes | Partial Yes | yes |
| 9Risk of bias assessed satisfactorilycritical | RCT: Yes · NRSI: N/A | NRSI: N/A · RCT: Yes | no |
| 10Funding of included studies reported | No | No | yes |
| 11Appropriate meta-analysis methodscritical | RCT: Yes · NRSI: N/A | NRSI: N/A · RCT: Yes | no |
| 12Impact of risk of bias on the pooled results | No | No | yes |
| 13Risk of bias accounted for in interpretationcritical | Yes | Yes | yes |
| 14Heterogeneity explained | Yes | Yes | yes |
| 15Publication bias investigatedcritical | Yes | Yes | yes |
| 16Conflicts of interest reported | Yes | Yes | yes |
| Overall | Critically Low | Critically Low | yes |